| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a clinical-stage biotechnology company that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Headquartered in Paris, Fra..
>Volltext.. |
| 9845.86 Mio. EUR |
| 9388.36 Mio. EUR |
| - |
| -262.99 Mio. EUR |
| -337.53 Mio. EUR |
| -4.6 EUR |
| 34.76 Mio. EUR |
| 485.08 Mio. EUR |
| -180.7 Mio. EUR |
| 7.9 |
| - |
| -124.85% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 28.07.26 |
|
||||
|
||||
|